Tempest Therapeutics
TPST
50 hedge funds and large institutions have $81.3M invested in Tempest Therapeutics in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 6 reducing their positions, and 2 closing their positions.
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
233% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 6
41% more capital invested
Capital invested by funds: $57.5M → $81.3M (+$23.7M)
22% more funds holding
Funds holding: 41 → 50 (+9)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$6.03M |
| 2 |
AIC
AWM Investment Company
New York
|
+$4.42M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$3.82M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.68M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$403K |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$370K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$148K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$10K |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
-$9.87K |
TPST Hedge Fund Activity: Q4 2019 in Review
50 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2019, worth a combined $81.3M — up 41% from $57.5M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TPST positions and 2 closed out — a net gain of 9 holders — while 20 added to existing stakes and 6 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $6.03M. The largest seller was Adams Street Partners, cutting an estimated $403K.
- 50 institutional investors held Tempest Therapeutics (TPST) as of Q4 2019, up from 41 in Q3 2019.
- Funds reported $81.3M of Tempest Therapeutics stock for Q4 2019, up 41% quarter-over-quarter.
- 11 funds opened new Tempest Therapeutics positions in Q4 2019 and 2 closed out, a net change of +9 holders.
- The largest Tempest Therapeutics buyer in Q4 2019 was Baker Bros. Advisors, an estimated $6.03M added.
- The largest Tempest Therapeutics seller in Q4 2019 was Adams Street Partners, an estimated $403K sold.
Based on aggregated 13F filings for Q4 2019.